ATE287710T1 - Verfahren zum modulieren der mikrozirkulation - Google Patents

Verfahren zum modulieren der mikrozirkulation

Info

Publication number
ATE287710T1
ATE287710T1 AT96919782T AT96919782T ATE287710T1 AT E287710 T1 ATE287710 T1 AT E287710T1 AT 96919782 T AT96919782 T AT 96919782T AT 96919782 T AT96919782 T AT 96919782T AT E287710 T1 ATE287710 T1 AT E287710T1
Authority
AT
Austria
Prior art keywords
pct
arginine
medicament
precursor
sec
Prior art date
Application number
AT96919782T
Other languages
English (en)
Inventor
Heinz Schneider
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE287710T1 publication Critical patent/ATE287710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
AT96919782T 1995-05-18 1996-05-17 Verfahren zum modulieren der mikrozirkulation ATE287710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510037.6A GB9510037D0 (en) 1995-05-18 1995-05-18 Improvements in or relating to organic compounds
PCT/EP1996/002124 WO1996036327A1 (en) 1995-05-18 1996-05-17 Method of modulating microcirculation

Publications (1)

Publication Number Publication Date
ATE287710T1 true ATE287710T1 (de) 2005-02-15

Family

ID=10774643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919782T ATE287710T1 (de) 1995-05-18 1996-05-17 Verfahren zum modulieren der mikrozirkulation

Country Status (10)

Country Link
US (1) US5902829A (de)
EP (1) EP0914110B1 (de)
JP (1) JP3908785B2 (de)
AT (1) ATE287710T1 (de)
CA (1) CA2215692C (de)
DE (1) DE69634269T2 (de)
ES (1) ES2236736T3 (de)
GB (1) GB9510037D0 (de)
PT (1) PT914110E (de)
WO (1) WO1996036327A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
EP0806207A4 (de) * 1995-01-18 2002-01-02 Taisho Pharmaceutical Co Ltd Heilmittel für ekzeem
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
CA2381095C (en) * 1998-10-06 2012-08-14 The University Of Manitoba Method for treating insulin resistance through hepatic nitric oxide
US6784209B1 (en) * 1999-10-18 2004-08-31 Muscletech Research And Development Inc. Food supplement for increasing lean mass and strength
EP1221865B1 (de) * 1999-10-18 2007-01-03 Muscletech Research and Development Inc. Nahrungsmittelzusatz zur zunahme der fettarmen körpermasse und kraft
US6423349B1 (en) 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
EP1195178B1 (de) * 2000-10-06 2006-03-22 D.M.G. Italia Srl Immunotrophische Preparation zur Behandlung von tonsilläre Hypertrophie
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
EP1591118A1 (de) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Verwendung von Melatonin zur Vorbeugung von postoperativen Komplikationen
US8445536B2 (en) * 2005-03-31 2013-05-21 Ajinomoto Co., Inc. Arginine-containing compositions and methods for increasing blood flow using same
AU2011221341B2 (en) * 2005-08-26 2013-11-28 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain
MX2008002623A (es) * 2005-08-26 2008-03-18 Nestec Sa Composiciones y metodos para mejorar la integridad vascular funcional, la supervivencia celular y para reducir la apoptosis en isquemia o despues de un episodio isquemico en el cerebro.
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PT2854841T (pt) 2012-06-04 2017-05-15 Diamedica Inc Isoformas de glicosilação da calicreína 1 em tecido humano
RU2541184C1 (ru) * 2013-09-23 2015-02-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией рекомбинантного эритропоэтина и розувастатина
AU2018230478A1 (en) 2017-03-09 2019-09-12 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE192037T1 (de) * 1989-12-29 2000-05-15 Braun Medical Inc Verwendung von arginin als immunstimulator
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
JPH04282313A (ja) * 1991-03-11 1992-10-07 Ajinomoto Co Inc 血圧降下剤
JPH04330011A (ja) * 1991-04-30 1992-11-18 Morishita Roussel Kk 末梢動脈閉塞症改善剤
JPH0638708A (ja) * 1992-05-15 1994-02-15 Earth Chem Corp Ltd ナトリウム吸収阻害剤、ナトリウム吸収阻害剤を含有する高血圧予防食品、及び高血圧治療剤
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same

Also Published As

Publication number Publication date
GB9510037D0 (en) 1995-07-12
MX9708873A (es) 1998-06-30
EP0914110A1 (de) 1999-05-12
DE69634269D1 (de) 2005-03-03
DE69634269T2 (de) 2006-03-30
PT914110E (pt) 2005-05-31
US5902829A (en) 1999-05-11
CA2215692C (en) 2007-09-25
WO1996036327A1 (en) 1996-11-21
JPH11505541A (ja) 1999-05-21
JP3908785B2 (ja) 2007-04-25
ES2236736T3 (es) 2005-07-16
CA2215692A1 (en) 1996-11-21
EP0914110B1 (de) 2005-01-26

Similar Documents

Publication Publication Date Title
ATE287710T1 (de) Verfahren zum modulieren der mikrozirkulation
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
YU209288A (en) Process for producing compound for treating, which contains azelastin for use in nose and/or eye
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
DE69800859T2 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE143947T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
DE69522702T2 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
CA2069202A1 (en) The use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine in vascular surgery
CZ176395A3 (en) The use of riluzol for preparing medicaments acceptable as antidotes against harmful effects of irradiation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914110

Country of ref document: EP

EEIH Change in the person of patent owner